111 related articles for article (PubMed ID: 11983519)
1. Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds.
Campos JM; Núñez MC; Sánchez RM; Gómez-Vidal JA; Rodríguez-González A; Báñez M; Gallo MA; Lacal JC; Espinosa A
Bioorg Med Chem; 2002 Jul; 10(7):2215-31. PubMed ID: 11983519
[TBL] [Abstract][Full Text] [Related]
2. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?
Campos J; Núñez MC; Conejo-García A; Sánchez-Martín RM; Hernández-Alcoceba R; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
Curr Med Chem; 2003 Jul; 10(13):1095-112. PubMed ID: 12678804
[TBL] [Abstract][Full Text] [Related]
3. Novel 4-amino bis-pyridinium and bis-quinolinium derivatives as choline kinase inhibitors with antiproliferative activity against the human breast cancer SKBR-3 cell line.
Gómez-Pérez V; McSorley T; See Too WC; Konrad M; Campos JM
ChemMedChem; 2012 Apr; 7(4):663-9. PubMed ID: 22278967
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1).
Schiaffino-Ortega S; Baglioni E; Mariotto E; Bortolozzi R; Serrán-Aguilera L; Ríos-Marco P; Carrasco-Jimenez MP; Gallo MA; Hurtado-Guerrero R; Marco C; Basso G; Viola G; Entrena A; López-Cara LC
Sci Rep; 2016 Mar; 6():23793. PubMed ID: 27029499
[TBL] [Abstract][Full Text] [Related]
5. Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line.
Sánchez-Martín R; Campos JM; Conejo-García A; Cruz-López O; Báñez-Coronel M; Rodríguez-González A; Gallo MA; Lacal JC; Espinosa A
J Med Chem; 2005 May; 48(9):3354-63. PubMed ID: 15857141
[TBL] [Abstract][Full Text] [Related]
6. Choline kinase inhibitory effect and antiproliferative activity of new 1,1',1"-(benzene-1,3,5-triylmethylene)tris[4-[(disubstituted)amino]pyridinium] tribromides.
Conejo-García A; Campos J; Sánchez RM; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
Eur J Med Chem; 2003 Jan; 38(1):109-16. PubMed ID: 12593921
[TBL] [Abstract][Full Text] [Related]
7. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase.
Campos J; del Carmen Núñez M; Rodríguez V; Entrena A; Hernández-Alcoceba R; Fernández F; Lacal JC; Gallo MA; Espinosa A
Eur J Med Chem; 2001 Mar; 36(3):215-25. PubMed ID: 11337100
[TBL] [Abstract][Full Text] [Related]
8. (Q)SAR studies to design new human choline kinase inhibitors as antiproliferative drugs.
Campos JM; Sánchez-Martín RM; Conejo-García A; Entrena A; Gallo MA; Espinosa A
Curr Med Chem; 2006; 13(11):1231-48. PubMed ID: 16712467
[TBL] [Abstract][Full Text] [Related]
9. QSAR of 1,1'-(1,2-ethylenebisbenzyl)bis(4-substitutedpyridinium) dibromides as choline kinase inhibitors: a different approach for antiproliferative drug design.
Campos J; Núñez MC; Rodríguez V; Gallo MA; Espinosa A
Bioorg Med Chem Lett; 2000 Apr; 10(8):767-70. PubMed ID: 10782682
[TBL] [Abstract][Full Text] [Related]
10. New non-symmetrical choline kinase inhibitors.
Schiaffino-Ortega S; López-Cara LC; Ríos-Marco P; Carrasco-Jimenez MP; Gallo MA; Espinosa A; Marco C; Entrena A
Bioorg Med Chem; 2013 Nov; 21(22):7146-54. PubMed ID: 24080101
[TBL] [Abstract][Full Text] [Related]
11. Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.
Conejo-García A; Báñez-Coronel M; Sánchez-Martín RM; Rodríguez-González A; Ramos A; Ramírez de Molina A; Espinosa A; Gallo MA; Campos JM; Lacal JC
J Med Chem; 2004 Oct; 47(22):5433-40. PubMed ID: 15481981
[TBL] [Abstract][Full Text] [Related]
12. New more polar symmetrical bipyridinic compounds: new strategy for the inhibition of choline kinase α1.
Castro-Navas FF; Schiaffino-Ortega S; Carrasco-Jimenez MP; Ríos-Marco P; Marco C; Espinosa A; Gallo MA; Mariotto E; Basso G; Viola G; Entrena-Guadix A; López-Cara LC
Future Med Chem; 2015; 7(4):417-36. PubMed ID: 25875870
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of new bispyridinium salts of 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazoles.
Martín-Cantalejo Y; Sáez B; Monterde MI; Murillo MT; Braña MF
Eur J Med Chem; 2011 Nov; 46(11):5662-7. PubMed ID: 21996467
[TBL] [Abstract][Full Text] [Related]
14. Bispyridinium cyclophanes: novel templates for human choline kinase inhibitors.
Conejo-García A; Campos JM; Sánchez-Martín RM; Gallo MA; Espinosa A
J Med Chem; 2003 Aug; 46(17):3754-7. PubMed ID: 12904080
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, theoretical calculations and biological evaluation of new non-symmetrical choline kinase inhibitors.
Rubio-Ruíz B; Conejo-García A; Ríos-Marco P; Carrasco-Jiménez MP; Segovia J; Marco C; Gallo MA; Espinosa A; Entrena A
Eur J Med Chem; 2012 Apr; 50():154-62. PubMed ID: 22348828
[TBL] [Abstract][Full Text] [Related]
16. A novel 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazol with antitumoral activity via cell cycle arrest and induction of apoptosis.
Báñez-Coronel M; Rodríguez-González A; Martín-Cantalejo Y; Sáez B; Soto J; Villa MJ; Braña MF; Lacal JC
Int J Oncol; 2004 Oct; 25(4):1097-103. PubMed ID: 15375561
[TBL] [Abstract][Full Text] [Related]
17. A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.
Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Lacal JC
Clin Transl Oncol; 2015 Jan; 17(1):74-84. PubMed ID: 25472447
[TBL] [Abstract][Full Text] [Related]
18. Lead optimization-hit expansion of new asymmetrical pyridinium/quinolinium compounds as choline kinase α1 inhibitors.
Rubbini G; Buades-Martín AB; Kimatrai-Salvador M; Entrena A; Gallo-Mezo MÁ; Ríos-Marco P; Marco C; Mattiuzzo E; Bortolozzi R; Mariotto E; Greco FA; Macchiarulo A; Carrasco-Jiménez MP; Viola G; López-Cara LC
Future Med Chem; 2018 Aug; 10(15):1769-1786. PubMed ID: 30043647
[TBL] [Abstract][Full Text] [Related]
19. NMR QSAR model for the analysis of 4-(5-arylamino-1,3,4-thiadiazol-2-yl)benzene-1,3-diols.
Matysiak J; Niewiadomy A; Paw B; Dybała I
Arch Pharm (Weinheim); 2011 May; 344(5):340-4. PubMed ID: 21290429
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
